| Bioactivity | Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research. | ||||||||||||
| Target | Fusion protein | ||||||||||||
| Invitro | Rilematovir is a small-molecule respiratory syncytial virus (RSV) fusion inhibitor currently under clinical evaluation in infants hospitalized for RSV infection. Rilematovir binds to RSV F protein in its prefusion conformation. Rilematovir displays very potent antiviral activity and low cytotoxicity. In addition to its activity against the RSV A2 strain, Rilematovir is also highly active against a number of RSV strains from both A and B subtypes. The EC50 in an RSV infection assay using HeLa cells is 460 pM[1]. | ||||||||||||
| In Vivo | Oral treatment of neonatal lambs with Rilematovir, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible[1]. | ||||||||||||
| Name | Rilematovir | ||||||||||||
| CAS | 1383450-81-4 | ||||||||||||
| Formula | C21H20ClF3N4O3S | ||||||||||||
| Molar Mass | 500.92 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Roymans D, et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017 Aug 1;8(1):167. |
Rilematovir
CAS: 1383450-81-4 F: C21H20ClF3N4O3S W: 500.92
Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.